Last updated on August 2019

A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)


Brief description of study

This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.

Only China and South Korea will remain open to recruiting.

Clinical Study Identifier: NCT03033511

Find a site near you

Start Over

Marin Cancer Care /ID# 159207

Greenbrae, CA United States
  Connect »

Ucsd /Id# 157764

La Jolla, CA United States
  Connect »

Icri /Id# 157765

Whittier, CA United States
  Connect »

Holy Cross Hospital /ID# 156716

Fort Lauderdale, FL United States
  Connect »

University of Florida /ID# 155799

Gainesville, FL United States
  Connect »

Billings Clinic /ID# 201788

Billings, MT United States
  Connect »

Cone Health /ID# 156689

Greensboro, NC United States
  Connect »

Cone Health /ID# 163612

Greensboro, NC United States
  Connect »

Inca /Id# 159658

Rio de Janeiro, Brazil
  Connect »

Iucpq /Id# 159530

Sainte-foy, QC Canada
  Connect »

PMI Euromedservice /ID# 159369

Pushkin, Russian Federation
  Connect »

LLC Novaya Clinica /ID# 205523

Pyatigorsk, Russian Federation
  Connect »

LLC BioEq Ltd. /ID# 159368

St. Petersburg, Russian Federation
  Connect »